JPRN-jRCTs031210158
Recruiting
Phase 2
A Prospective Interventional Study to Evaluate the Efficacy and Safety of Intraoperative Fluorescence Diagnosis Using 5-ALA in Meningioma surgery
Masahide Matsuda0 sites22 target enrollmentJune 22, 2021
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- meningioma
- Sponsor
- Masahide Matsuda
- Enrollment
- 22
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients who meet all of the following criteria are eligible
- •1\) Patients undergoing surgical removal of a first or recurrent (regardless of prior treatment, any number of recurrences are acceptable) brain tumor with meningioma as the primary differential.
- •2\) Patients scheduled for maximal resection by surgery (excluding biopsy, etc.)
- •3\) Age 20 years or older on the date of consent, regardless of gender.
- •4\) Either (a) or (b) below applies.
- •(a) Most suspicious for recurrent meningioma
- •(b) One or more of the following imaging findings on preoperative imaging: infiltration of the surrounding brain or bone, hyperostosis or bony destruction of the surrounding skull, extracranial extension of the tumor, marked cerebral edema around the tumor, cystic change within or around the tumor, irregularity of the tumor border, presence of peritumoral satellite lesions.
- •5\) Patients who have received sufficient explanation and understanding of the contents of this study, and who have given written consent of their own free will (substitute consent is not permitted, but substitute writing is permitted for patients who have difficulty writing due to paralysis, etc.)
Exclusion Criteria
- •Patients with any of the following conditions will not be included in this study
- •1\) Patients with hypersensitivity to 5\-ALA or porphyrins
- •2\) Patients with porphyria or a history of photosensitivity
- •3\) Patients who have received 5\-ALA or Talaporfin sodium within one month of the scheduled administration of the study drug
- •4\) Patients with serious conditions or complications of systemic diseases that may interfere with the safe performance of general anesthesia or craniotomy
- •5\) Patients with serious cardiovascular diseases (myocardial infarction, unstable angina, valvular disease, heart failure, etc.) that require special attention in perioperative management
- •6\) Patients with serious liver disease or liver enzyme abnormalities \[AST (GOT) or ALT (GPT) 100 IU/L or higher]
- •7\) Patients with serious renal dysfunction (serum creatinine 1\.5 mg/dL or higher)
- •8\) Positive for HBs antigen, HCV antibody, or HIV antibody
- •9\) Women who are pregnant or may become pregnant
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
APPRECIATEJPRN-jRCTs031210665Kawahito Yutaka55
Not yet recruiting
Not Applicable
Saving joint and minimizing recurrence rate of grade 3 GCTHealth Condition 1: C408- Malignant neoplasm of overlappingsites of bone and articular cartilage of limbHealth Condition 2: O- Medical and SurgicalHealth Condition 3: M898- Other specified disorders of boneCTRI/2022/10/046435Department of orthopedics
Recruiting
Phase 2
A prospective interventional study to evaluate the validity of sentinel node biopsy for omitting axillary dissection after neoadjuvant chemotherapy for breast cancer patients with axillary lymph node metastasisJPRN-UMIN000048307Cancer Institute Hospital of JFCR Breast Surgical Oncology, Breast Oncology center80
Recruiting
Not Applicable
Evaluation of efficacy and safety of postoperative proton beam therapy for resectable pancreatic cancerBorderline resectable or unresectable locally advanced pancreatic cancerJPRN-UMIN000051399Hyogo Ion Beam Medical Center40
Recruiting
Not Applicable
A prospective interventional study evaluating the safety and efficacy of trans-nasal hybrid endoscopic submucosal dissection for the treatment of early gastric cancerearly gastric cancer/adenomaJPRN-UMIN000032615TT Medical Center Tokyo20